Despite Limitations, Oral Mobocertinib Offers Ongoing Benefits for Lung Cancer Subset, Says Expert
November 30th 2022An expert from NYU Langone in New York City recently discussed the strengths and limitations of the oral tyrosine kinase inhibitor mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion+ metastatic non-small cell lung cancer.
Joel W. Neal, MD, PhD Discusses the Data on Cabozantinib and Atezolizumab Use in Advanced NSCLC
September 28th 2022In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.
Hossein Borghaei, DO, MS, Discusses Future Research Directions in NSCLC Based on the Lung-MAP Trial
September 14th 2022Hossein Borghaei, DO, MS, discussed where investigators may drive future research following the phase 2 Lung-MAP trial examining pembrolizumab and ramucirumab in previously treated advanced non–small cell lung cancer.
Roy S. Herbst, MD, PhD, Reviews Ramucirumab Plus Pembrolizumab in ICI-Resistant NSCLC
August 3rd 2022At 2022 ASCO, Roy S. Herbst, MD, PhD, spoke about the results of a Lung-MAP substudy showing benefit of ramucirumab plus pembrolizumab vs standard of care chemotherapy for patients with advanced non–small cell lung cancer who demonstrated resistance to prior immunotherapy.
Promising EFS Noted Following Neoadjuvant Nivo/Chemo in Resectable NSCLC Following pCR
July 1st 2022Patients with stage IB to IIA non–small cell lung cancer who experienced a pathologic complete response to neoadjuvant nivolumab plus platinum-based doublet chemotherapy experienced a prolonged event-free survival.
Karen L. Reckamp, MD, Examines Safety of Ramucirumab Plus Pembrolizumab in IO/Chemo-Pretreated NSCLC
June 19th 2022Karen L. Reckamp, MD, spoke about safety signals that emerged in the Lung-MAP nonmatched phase 2 substudy S1800A and what the next steps are for the combination of ramucirumab/pembrolizumab in patients with non–small cell lung cancer pretreated with chemotherapy and immunotherapy
Frontline Sugemalimab Plus Chemo Combo Illicits Greater Survival Vs Chemo Alone in NSCLC
June 7th 2022Without regard for tumor pathology or PD-L1 expression, administering sugemalimab in combination with chemotherapy was superior to chemotherapy alone in treating patients with non–small cell lung cancer.
Best Responses With Pembrolizumab Monotherapy Observed in NSCLC With 90% or Higher PD-L1 Expression
June 7th 2022Results from a correlative analysis conducted with 3-years of follow-up showed pembrolizumab monotherapy resulted in the greatest long-term survival benefit in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more.
Pembrolizumab Improves DFS in Completely Resected Early-Stage NSCLC Across Subgroups
June 6th 2022Results from the phase 3 PEARLS/KEYNOTE-091 trial showed improved disease-free survival with pembrolizumab vs placebo for patients with completely resected early-stage non–small cell lung cancer, without regard surgical treatment, extent of disease, or adjuvant chemotherapy.